Biomaterials Research,
Journal Year:
2024,
Volume and Issue:
28
Published: Jan. 1, 2024
During
the
COVID-19
pandemic,
mRNA
vaccines
emerged
as
a
rapid
and
effective
solution
for
global
immunization.
The
success
of
has
increased
interest
in
use
lipid
nanoparticles
(LNPs)
vivo
delivery
therapeutics.
Although
exhibits
robust
expression
profiles,
transient
protein
is
often
observed,
raising
uncertainty
regarding
frequency
its
administration.
Additionally,
various
RNA
therapeutics
may
necessitate
repeated
dosing
to
achieve
optimal
therapeutic
outcomes.
Nevertheless,
impact
administrations
mRNA/LNP
on
immune
responses
efficacy
remains
unclear.
In
this
study,
we
investigated
influence
formulation
parameters,
specifically
ionizable
lipids
polyethylene
glycol
(PEG)
lipids,
repeat
administration
mRNA/LNP.
Our
findings
revealed
that
had
no
discernible
dose-responsive
administrations,
whereas
structure
molar
ratio
PEG
were
primary
factors
affected
performance.
optimization
LNP
with
confirmed
sustained
after
administrations.
This
study
highlights
critical
importance
optimizing
formulations
requiring
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(15)
Published: Jan. 17, 2024
In
the
past
decade,
adoptive
cell
therapy
with
chimeric
antigen
receptor-T
(CAR-T)
cells
has
revolutionized
cancer
treatment.
However,
complexity
and
high
costs
involved
in
manufacturing
current
greatly
inhibit
its
widespread
availability
access.
To
address
this,
situ
therapy,
which
directly
reprograms
immune
inside
body,
recently
been
developed
as
a
promising
alternative.
Here,
an
overview
of
recent
progress
development
synthetic
nanomaterials
is
provided
to
deliver
plasmid
DNA
or
mRNA
for
reprogramming
T
macrophages,
focusing
especially
on
CAR
therapies.
Also,
main
challenges
are
discussed
some
approaches
overcome
these
barriers
fulfill
clinical
applications
proposed.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(11), P. 1376 - 1376
Published: Oct. 26, 2024
Oils
and
lipids
help
make
water-insoluble
drugs
soluble
by
dispersing
them
in
an
aqueous
medium
with
the
of
a
surfactant
enabling
their
absorption
across
gut
barrier.
The
emergence
microemulsions
(thermodynamically
stable),
nanoemulsions
(kinetically
self-emulsifying
drug
delivery
systems
added
unique
characteristics
that
suitable
for
prolonged
storage
controlled
release.
In
1990s,
solid-phase
were
introduced
to
reduce
leakage
from
nanoparticles
prolong
Manipulating
structure
emulsions
solid
lipid
has
enabled
multifunctional
loading
therapeutic
macromolecules
such
as
proteins,
nucleic
acid,
vaccines,
etc.
Phospholipids
surfactants
well-defined
polar
head
carbon
chain
have
been
used
prepare
bilayer
vesicles
known
liposomes
niosomes,
respectively.
increasing
knowledge
targeting
ligands
external
factors
gain
control
over
pharmacokinetics
ever-increasing
number
synthetic
are
expected
vesicular
preferred
choice
encapsulation
targeted
agents.
This
review
discusses
different
oil-based
nanoparticulate
drugs.
salient
features
each
system
highlighted,
special
emphasis
is
given
studies
compare
them.
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2025,
Volume and Issue:
13
Published: March 12, 2025
The
advent
of
mRNA
vaccines,
accelerated
by
the
global
response
to
COVID-19
pandemic,
marks
a
transformative
shift
in
vaccine
technology.
In
this
article,
we
discuss
development,
current
applications,
and
prospects
vaccines
for
both
prevention
treatment
infectious
diseases
oncology.
By
leveraging
capacity
encode
antigens
within
host
cells
directly,
provide
versatile
scalable
platform
suitable
addressing
broad
spectrum
pathogens
tumor-specific
antigens.
We
highlight
recent
advancements
design,
innovative
delivery
mechanisms,
ongoing
clinical
trials,
with
particular
emphasis
on
their
efficacy
combating
diseases,
such
as
COVID-19,
Zika,
influenza,
well
emerging
potential
cancer
immunotherapy.
also
address
critical
challenges,
including
stability,
optimization
immune
responses,
broader
issue
accessibility.
Finally,
review
strategies
advancing
next-generation
aim
overcoming
limitations
technology
enhancing
preventive
therapeutic
approaches
oncological
diseases.
Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
165, P. 115091 - 115091
Published: July 6, 2023
Metastasis
accounts
for
the
majority
of
cancer-associated
mortalities,
representing
a
huge
health
and
economic
burden.
One
mechanisms
that
enables
metastasis
is
hypersialylation,
characterized
by
an
overabundance
sialylated
glycans
on
tumor
surface,
which
leads
to
repulsion
detachment
cells
from
original
tumor.
Once
are
mobilized,
hijack
natural
killer
T-cells
through
self-molecular
mimicry
activatea
downstream
cascade
molecular
events
result
in
inhibition
cytotoxicity
inflammatory
responses
against
cancer
cells,
ultimately
leading
immune
evasion.
Sialylation
mediated
family
enzymes
known
as
sialyltransferases
(STs),
catalyse
transfer
sialic
acid
residue
donor,
CMP-sialic
acid,
onto
terminal
end
acceptor
such
N-acetylgalactosamine
cell-surface.
Upregulation
STs
increases
hypersialylation
up
60%
considered
distinctive
hallmark
several
types
cancers
pancreatic,
breast,
ovarian
cancer.
Therefore,
inhibiting
has
emerged
potential
strategy
prevent
metastasis.
In
this
comprehensive
review,
we
discuss
recent
advances
designing
novel
sialyltransferase
inhibitors
using
ligand-based
drug
design
high-throughput
screening
synthetic
entities,
emphasizing
most
successful
approaches.
We
analyse
limitations
challenges
selective,
potent,
cell-permeable
ST
hindered
further
development
into
clinical
trials.
conclude
analysing
emerging
opportunities,
including
advanced
delivery
methods
increase
these
enrich
clinics
with
therapeutics
combat
Frontiers in Chemistry,
Journal Year:
2023,
Volume and Issue:
11
Published: Sept. 28, 2023
The
use
of
biomaterials
in
delivering
CRISPR/Cas9
for
gene
therapy
infectious
diseases
holds
tremendous
potential.
This
innovative
approach
combines
the
advantages
with
protective
properties
biomaterials,
enabling
accurate
and
efficient
editing
while
enhancing
safety.
Biomaterials
play
a
vital
role
shielding
components,
such
as
lipid
nanoparticles
or
viral
vectors,
from
immunological
processes
degradation,
extending
their
effectiveness.
By
utilizing
flexibility
tailored
systems
can
be
designed
to
address
specific
genetic
diseases,
paving
way
personalized
therapeutics.
Furthermore,
this
delivery
method
offers
promising
avenues
combating
illnesses
by
precisely
modifying
pathogen
genomes,
reducing
pathogenicity.
facilitate
site-specific
modifications,
ensuring
effective
infected
cells
minimizing
off-target
effects.
However,
challenges
remain,
including
optimizing
efficiency,
effects,
long-term
safety,
establishing
scalable
production
techniques.
Thorough
research,
pre-clinical
investigations,
rigorous
safety
evaluations
are
imperative
successful
translation
laboratory
clinical
applications.
In
review,
we
discussed
how
using
revolutionizes
disease
treatment,
offering
precise
safe
capabilities
potential
significantly
improve
human
health
quality
life.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Nov. 14, 2024
Abstract
In
the
last
decade,
messenger
ribonucleic
acid
(mRNA)-based
drugs
have
gained
great
interest
in
both
immunotherapy
and
non-immunogenic
applications.
This
surge
can
be
largely
attributed
to
demonstration
of
distinct
advantages
offered
by
various
mRNA
molecules,
alongside
rapid
advancements
nucleic
delivery
systems.
It
is
noteworthy
that
immunogenicity
presents
a
double-edged
sword.
context
immunotherapy,
extra
supplementation
adjuvant
generally
required
for
induction
robust
immune
responses.
Conversely,
non-immunotherapeutic
scenarios,
activation
unwanted
considering
host
tolerability
high
expression
demand
mRNA-encoded
functional
proteins.
Herein,
mainly
focused
on
linear
non-replicating
mRNA,
we
overview
preclinical
clinical
progress
prospects
medicines
encompassing
vaccines
other
therapeutics.
We
also
highlight
importance
focusing
host-specific
variations,
including
age,
gender,
pathological
condition,
concurrent
medication
individual
patient,
maximized
efficacy
safety
upon
administration.
Furthermore,
deliberate
potential
challenges
may
encounter
realm
disease
treatment,
current
endeavors
improvement,
as
well
application
future
advancements.
Overall,
this
review
aims
present
comprehensive
understanding
mRNA-based
therapies
while
illuminating
prospective
development
drugs.
Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
14(7), P. 2885 - 2900
Published: April 22, 2024
Inherited
genetic
disorders
of
the
liver
pose
a
significant
public
health
burden.
Liver
transplantation
is
often
limited
by
availability
donor
livers
and
exorbitant
costs
immunosuppressive
therapy.
To
overcome
these
limitations,
nucleic
acid
therapy
provides
hopeful
alternative
that
enables
gene
repair,
supplementation,
silencing
with
suitable
vectors.
Though
viral
vectors
are
most
efficient
preferred
for
therapy,
pre-existing
immunity
debilitating
immune
responses
limit
their
use.
As
potential
alternative,
lipid
nanoparticle-mediated
being
explored
to
deliver
multiple
forms,
including
pDNA,
mRNA,
siRNA,
proteins.
Herein,
we
discuss
broader
applications
nanoparticles,
from
protein
replacement
restoring
disease
mechanism
through
delivery
editing,
as
well
preclinical
clinical
studies
transplantation.
Frontiers in Immunology,
Journal Year:
2023,
Volume and Issue:
14
Published: Nov. 28, 2023
Macrophages
and
neutrophils
are
the
main
components
of
innate
immune
system
play
important
roles
in
promoting
angiogenesis,
extracellular
matrix
remodeling,
cancer
cell
proliferation,
metastasis
tumor
microenvironment
(TME).
They
can
also
be
harnessed
to
mediate
cytotoxic
killing
effects
orchestrate
effective
anti-tumor
responses
with
proper
stimulation
modification.
Therefore,
macrophages
have
strong
potential
immunotherapy.
In
this
review,
we
briefly
outlined
applications
or
adoptive
therapies,
focused
on
chimeric
antigen
receptor
(CAR)-engineered
(CAR-Ms)
(CAR-Ns).
We
summarized
construction
strategies,
preclinical
clinical
studies
CAR-Ms
CAR-Ns.
end,
discussed
limitations
challenges
CAR-Ns,
as
well
future
research
directions
extend
their
treating
solid
tumors.
